News

Encoded Therapeutics has received clearance from U.S. and Australian regulatory agencies to launch Phase 1/2 clinical trials testing ETX101, its Dravet syndrome gene therapy candidate, in infants and young children with the seizure disorder. In the U.S., the company plans to begin ENDEAVOR (NCT05419492), which will be…

International Epilepsy Day for 2024 aims to promote public understanding of a condition thought to affect some 65 million people globally — including those with Dravet syndrome — to gather support for a 10-year World Health Organization (WHO) epilepsy roadmap. Held annually on the second Monday in February —…

Fintepla (fenfluramine) eased brain inflammation, protected nerve cells from damage and death, and extended survival in a mouse model of Dravet syndrome, a study showed. “These results support clinical observations that [Fintepla] may have benefits beyond seizures,” its scientists wrote. The article, “Fenfluramine increases survival…

Real-world use of Fintepla (fenfluramine) was found to be safe and effective for people with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), according to a recent report from Spain. Data, which showed that 60.3% of Dravet patients experienced a clinically meaningful reduction in seizures, are generally consistent with…

Treatment with Fintepla (fenfluramine) appeared to be reasonably safe and to effectively lower seizure frequency in five young children with Dravet syndrome who started on the therapy before they were 2 years old, scientists in Italy reported. These findings are especially noteworthy because, in…

Most Dravet syndrome patients utilize various types of therapies beyond medicines to manage the disease, including physiotherapy, occupational therapy, and psychological therapy, according to a recent survey of caregivers and family members in Spain. While survey respondents sometimes found these non-pharmacological interventions to be effective, sizable numbers were less…

Available treatments aren’t enough to fully control seizures for most people with Dravet syndrome, and most have side effects that can worsen their quality of life. That’s according to a new study funded by Takeda. A team led by scientists at the company presented the work at the…

Epidiolex (cannabidiol), an approved treatment for seizures in Dravet syndrome, may in some rare cases cause side effects including clusters of seizures, vision impairment, and problems with speech. That’s according to a new study, “Adverse Events of Epidiolex: A Real-world Drug Safety Surveillance Study based…

Treatment with a noninvasive procedure called transcranial static magnetic stimulation (tSMS) led to significantly less seizure activity in a mouse model of Dravet syndrome. “Our results show that tSMS, a non-invasive neuromodulatory technique, can reduce the number, duration, and severity of [seizures] in a mouse model of” Dravet,…

STK-001, an investigational treatment for children and adolescents with Dravet syndrome, markedly reduced seizure frequency and improved cognition and behavior, according to new findings in Phase 1/2a clinical trials. “The substantial and sustained reductions in seizure frequency and improvements in cognition and behavior observed in our STK-001 clinical studies…